Your browser doesn't support javascript.
Clinical outcome of COVID-19 in patients with adult congenital heart disease.
Schwerzmann, Markus; Ruperti-Repilado, Francisco Javier; Baumgartner, Helmut; Bouma, Berto; Bouchardy, Judith; Budts, Werner; Campens, Laurence; Chessa, Massimo; Del Cerro Marin, Maria Jesús; Gabriel, Harald; Gallego, Pastora; Garcia-Orta, Rocio; Gonzalez, Ana Elvira; Jensen, Annette Schophuus; Ladouceur, Magalie; Miranda-Barrio, Berta; Morissens, Marielle; Pasquet, Agnes; Rueda, Joaquín; van den Bosch, Annemien E; van der Zwaan, Heleen Berdina; Tobler, Daniel; Greutmann, Matthias.
  • Schwerzmann M; Center for Congenital Heart Disease, Inselspital University Hospital, Bern, Switzerland markus.schwerzmann@med.unibe.ch.
  • Ruperti-Repilado FJ; Center for Congenital Heart Disease, Inselspital University Hospital, Bern, Switzerland.
  • Baumgartner H; Dept. of Cardiology III - Adult Congenital and Valvular Heart Disease, University Hospital Muenster, Munster, Nordrhein-Westfalen, Germany.
  • Bouma B; Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands.
  • Bouchardy J; Department of Cardiology and Cardiac Surgery, Lausanne University Hospital, Lausanne, Switzerland.
  • Budts W; Division of Cardiology, University Hospital of Geneva, Geneva, Switzerland.
  • Campens L; Congenital and Structural Cardiology, University Hospital Leuven, Leuven, Flanders, Belgium.
  • Chessa M; Department of Cardiovascular Sciences, Catholic University Leuven, Leuven, Flanders, Belgium.
  • Del Cerro Marin MJ; Department of Cardiology, Ghent University Hospital, Gent, Oost-Vlaanderen, Belgium.
  • Gabriel H; ACHD UNIT - Pediatric and Adult Congenital Heart Centre, IRCCS - Policlinico San Donato, San Donato Milanese - Milan, Lombardia, Italy.
  • Gallego P; Pediatric Cardiology and GUCH Centre, Ramon y Cajal University Hospital, Madrid, Spain.
  • Garcia-Orta R; Department of Cardiology, Medical University of Vienna, Vienna, Austria.
  • Gonzalez AE; Adult Congenital Heart Disease Unit, Department of Cardiology, Hospital Universitario, Virgen del Rocio, Instituto de BioMedicina de Sevilla (IBIS) and CIBERCV, Sevilla, Spain.
  • Jensen AS; Adult Congenital Heart Disease Unit, Department of Cardiology, Hospital Universitario Virgen de las Nieves. 2 Instituto de Investigación Biosanitaria ibs, Granada, Andalucía, Spain.
  • Ladouceur M; Hospital Universitario La Paz, Madrid, Spain.
  • Miranda-Barrio B; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Morissens M; Adult Congenital Heart Disease Unit, Centre de référence des Malformations Cardiaques Congénitales Complexes, M3C, Université de Paris, Hôpital Européen Georges Pompidou, AP-H, Paris, France.
  • Pasquet A; Integrated Adult Congenital Heart Disease Unit, Vall d'Hebron University Hospital and Santa Creu i Sant Pau University Hospital, Barcelona, Spain.
  • Rueda J; Department of Cardiology, CHU Brugmann, Brussels, Belgium.
  • van den Bosch AE; Department of Cardiology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium.
  • van der Zwaan HB; Adult Congenital Heart Disease Unit, Department of Cardiology, Hospital Universitari i Politècnic La Fe and CIBERCV, Valencia, Comunidad Valenciana, Spain.
  • Tobler D; Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands.
  • Greutmann M; Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Heart ; 2021 Mar 08.
Article in English | MEDLINE | ID: covidwho-1123609
ABSTRACT

AIMS:

Patients with adult congenital heart disease (ACHD) are a potentially vulnerable patient cohort in case of COVID-19. Some cardiac defects may be associated with a poor COVID-19 outcome. Risk estimation in ACHD is currently based on expert opinion. The aim of this study was to collect clinical outcome data and to identify risk factors for a complicated course of COVID-19 in patients with ACHD.

METHODS:

Twenty-five ACHD centres in nine European countries participated in the study. Consecutive patients with ACHD diagnosed with COVID-19 presenting to one of the participating centres between 27 March and 6 June 2020 were included. A complicated disease course was defined as hospitalisation for COVID-19 requiring non-invasive or invasive ventilation and/or inotropic support, or a fatal outcome.

RESULTS:

Of 105 patients with a mean age of 38±13 years (58% women), 13 had a complicated disease course, of whom 5 died. In univariable analysis, age (OR 1.3, 95% CI 1.1 to 1.7, per 5 years), ≥2 comorbidities (OR 7.1, 95% CI 2.1 to 24.5), body mass index of >25 kg/m2 (OR 7.2, 95% CI 1.9 to 28.3) and cyanotic heart disease (OR 13.2, 95% CI 2.5 to 68.4) were associated with a complicated disease course. In a multivariable logistic regression model, cyanotic heart disease was the most important predictor (OR 60.0, 95% CI 7.6 to 474.0).

CONCLUSIONS:

Among patients with ACHD, general risk factors (age, obesity and multiple comorbidities) are associated with an increased risk of complicated COVID-19 course. Congenital cardiac defects at particularly high risk were cyanotic lesions, including unrepaired cyanotic defects or Eisenmenger syndrome.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal subject: Cardiology Year: 2021 Document Type: Article Affiliation country: Heartjnl-2020-318467

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal subject: Cardiology Year: 2021 Document Type: Article Affiliation country: Heartjnl-2020-318467